Brokerages expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report sales of $240,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Abeona Therapeutics’ earnings, with estimates ranging from $200,000.00 to $300,000.00. Abeona Therapeutics posted sales of $260,000.00 during the same quarter last year, which suggests a negative year-over-year growth rate of 7.7%. The company is scheduled to report its next earnings report on Friday, March 30th.
On average, analysts expect that Abeona Therapeutics will report full-year sales of $240,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $900,000.00. For the next financial year, analysts expect that the company will post sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.22 million.
A number of equities analysts have issued reports on ABEO shares. Zacks Investment Research raised Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Jefferies Group reaffirmed a “buy” rating and issued a $28.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a report on Monday, November 20th. Finally, SunTrust Banks started coverage on Abeona Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $27.11.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded up $0.45 on Friday, reaching $12.50. The company’s stock had a trading volume of 1,575,224 shares, compared to its average volume of 1,541,897. Abeona Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $22.75. The firm has a market cap of $584.69, a PE ratio of -18.94 and a beta of 1.23.
Several hedge funds have recently modified their holdings of ABEO. Teacher Retirement System of Texas acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $163,000. Rhumbline Advisers acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $190,000. MetLife Investment Advisors LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $194,000. SG Americas Securities LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $218,000. Finally, Virtu Financial LLC acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at about $246,000. 41.99% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/18/abeona-therapeutics-inc-abeo-expected-to-post-quarterly-sales-of-240000-00.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.